Welcome to our dedicated page for Orthofix Med news (Ticker: OFIX), a resource for investors and traders seeking the latest updates and insights on Orthofix Med stock.
Orthofix Medical Inc. reports developments across its orthopedic and spine medical technology portfolio. The company provides spinal implants, therapeutic solutions, limb reconstruction systems, biologics and enabling technologies, including the 7D FLASH Navigation System, for complex musculoskeletal conditions.
Recurring OFIX news includes quarterly results, guidance, product launches and commercial execution in Spine and Orthopedics. Company updates also cover pediatric limb reconstruction offerings such as FITBONE, planning software such as OrthoNext, the TRUELOK Elevate system, spine leadership realignment, distributor transitions, biologics activity and the discontinued M6 artificial disc product lines.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Orthofix Medical Inc. (NASDAQ:OFIX) will release its first quarter 2023 financial results on May 9, 2023, after market close. A conference call to discuss these results will take place at 4:30 p.m. ET on the same day, with access details available for interested parties. The newly merged Orthofix-SeaSpine organization is recognized as a leader in the global spine and orthopedics sector, offering a diverse range of products distributed across approximately 68 countries. The company is headquartered in Lewisville, Texas, and maintains a focus on innovation in spine and biologics products, with significant presence across multiple locations including California and Europe.
Orthofix Medical Inc (NASDAQ: OFIX) announced the full commercial launch of two innovative access retractor systems, the Lattus™ Lateral Access System and the Fathom™ Pedicle-Based Retractor System, aimed at enhancing minimally invasive spine (MIS) surgeries, targeting a market valued at approximately $1.8 billion.
The Lattus system emphasizes user-friendliness and versatility, improving access and procedural efficiency for spine surgeries. Meanwhile, the Fathom system allows for precise control over blade adjustments, enhancing surgical outcomes. Both systems are designed to integrate seamlessly with Orthofix's existing products, demonstrating the company's commitment to delivering comprehensive solutions in the operating room.
Orthofix Medical Inc (NASDAQ:OFIX) announced that its Fitbone™ TAA intramedullary limb-lengthening system has surpassed 5,000 implants, with over 20 years of clinical safety and efficacy evidence. This system addresses limb length discrepancies through a minimally invasive procedure. The Fitbone system is available in the U.S. under FDA 510(k) clearance and holds a pediatric indication, making it unique in the market. Orthofix is positioned as a leader in internal and external fixation solutions for limb reconstruction, targeting innovative treatment options for patients with deformities.